In October 2008, OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under the terms of the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’s drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.